On March 24, 2025 IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, reported that interim results from the Company’s ICESECRET study of cryoablation for patients with small renal masses ("SRM") who cannot be offered kidney preserving surgery were presented at the European Association of Urology Conference in Madrid, Spain which took place March 21-24, 2025 (Press release, IceCure Medical, MAR 24, 2025, View Source [SID1234651381]). The oral presentation titled "Safety and efficacy of cryoablation in small renal masses, using liquid nitrogen-based cryoablation system: ICESECRET Study Interim analysis" was delivered by Dr. Nasir Said of Bnai Zion Medical Center, Israel.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased to see these impressive data shared at a major urology conference in Europe, where ProSense is approved for renal tumors" stated Eyal Shamir, IceCure’s Chief Executive Officer. "These data support the adoption of cryoablation as a safe and effective option for patients who are otherwise ineligible for kidney preserving surgery, a large unmet need." Conclusions and data in the presentation included the following:
Cryoablation is a viable alternative for SRMs, especially for tumors ≤3 cm;
111 patients were evaluated at a mean follow-up of approximately 3 years;
Recurrence free rate was 88.7% in patients with tumors ≤3 cm, low risk and a successful procedure at a mean follow up of 3.4 years;
Recurrence free rate was 87.8% in patients with tumors ≤3 cm at low risk with at a mean follow up of 3.4 years;
Recurrence free rate was 87.2% in patients with tumor size ≤3 cm at a mean follow up of 3.5 years;
Safety results include 17 mild adverse events, 3 moderate events, and 1 severe complication observed; and
The mean age of the patients was 69 and 84.2% had comorbidities, the most common of which were hypertension (77%) and diabetes (47%).
ProSense is approved for benign and malignant kidney tumors in the U.S., Europe, and numerous other countries.
About ICESECRET
ICESECRET, a prospective, multicenter, single-arm clinical trial is being performed at Bnai Zion Medical Center in Haifa, Israel and Shamir Medical Center in Be’er Ya’akov, Israel and is being led by Principal Investigator Prof. Halahmi Sarel. The trial includes 114 patients (138 lesions) with localized SRM of ≤5 cm that were ablated with ProSense cryoablation under CT guidance. Follow-up visits are performed six weeks, six months, one year, and then annually up to five years after the procedure. During the follow-up visits, data related to local recurrence, based on CT imaging, is collected. Safety was determined by monitoring procedure-related adverse events throughout the study.
About ProSense
The ProSense Cryoablation System is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
ProSense enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense opens that door to fast and convenient office-based procedures for breast tumors.